



Combiquick

HIV/HCV



Setting a New Trend in Rapid Testing

It is estimated that Hepatitis C has infected nearly 270-300 million people worldwide and infects 3-4 million more people per year. Most of these persons are chronically infected and might not be aware of their infection because they are not clinically ill. Infected persons serve as a source of transmission to others and are at risk for chronic liver disease or other HCV-related chronic diseases. Co-infection with HIV is common and rates among HIV positive populations are higher. The prevalence of HCV infection among all HIV-infected individuals can be as high as 40%¹.

CDC Recommendation

Patients with HIV infection should be evaluated for the presence of HCV

Tulip introduces yet another innovative platform

CombiQuic

HIV/HCV

A rapid qualitative immunoconcentration test for detection of antibodies to HIV 1/2 & HCV in human serum/plasma

Convenience

- COMBIQUIC detects both HIV & HCV in a single device.

Detects both HIV 1 & 2 antibodies

- COMBIQUIC employs synthetic peptide gp 41, gp 120 for HIV 1 & gp 36 for HIV 2.

Detects all 6 genotype of HCV

- COMBIQUIC employs genotype cross-reactive recombinant antigen from Core, NS3, NS4 & NS5 region.

High Sensitivity

- COMBIQUIC uses Affinity Bonded Tetravalent Spacer for achieving high epitope density for correct antigen orientation.

High Specificity

- COMBIQUIC uses interference corrected Protein-A gold conjugate.

Minimizes Biohazard risk to user

- COMBIQUIC utilizes single drop of specimen for HIV & HCV testing.

Reliable

- Excellent correlation with EIA ● DCGI Approved



Performance of CombiQuic HIV/HCV

Comparison with Licensed EIA

Parameter	HIV 1 & 2	HCV
Sensitivity	100.00 %	100.00 %
Specificity	100.00 %	99.61 %

Reference:

1. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease*. MMWR 1998;47(RR-19):1-39.
2. Chapter 4 - Hepatitis, Viral, Type C - Yellow Book, CDC Health Information for International Travel 2008
3. Hepatitis C Infection, The National Institute on Drug Abuse (NIDA)
4. Data on file - Qualpro Diagnostics

For further information contact :

ISO 13485
Certified Company



TULIP DIAGNOSTICS (P) LTD.

Gitanjali, Tulip Block, Dr. Antonio do Rego Bagh, Alto Santacruz, Bambolim Complex Post Office, Goa - 403 202, INDIA.
Tel.: +91 832 2458546-50 Fax : +91 832 2458544 E-mail : sales@tulipgroup.com Website : www.tulipgroup.com